| Literature DB >> 30184037 |
Álvaro M Rösler1,2, Jonathan Fraportti1, Pedro Nectoux1, Gabriel Constantin1, Sílvio Cazella2, Mauro Ricardo Pontes Nunes1,2, Fernando A Lucchese1.
Abstract
INTRODUCTION: The interest in Expert systems has increased in the medical area. Some of them are employed even for diagnosis. With the variability of transcatheter prostheses, the most appropriate choice can be complex. This scenario reveals an enabling environment for the use of an Expert system. The goal of the study was to develop an Expert system based on artificial intelligence for supporting the transcatheter aortic prosthesis selection.Entities:
Mesh:
Year: 2018 PMID: 30184037 PMCID: PMC6122758 DOI: 10.21470/1678-9741-2018-0072
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1Expert system for the selection of the CoreValve transcatheter prosthesis.
CoreValve variables and patterns used to select the ideal prosthesis.
| Prosthesis | Annulus | Annulus | Annulus | Ascending | Valsalva |
|---|---|---|---|---|---|
| 23 | 18 - 20 mm | 254 - 314 mm2 | 56.4 - 62.8 mm | ≤ 34 mm | ≥ 25 mm |
| 26 | 20 - 23 mm | 314 - 415 mm2 | 62.8 - 72.3 mm | ≤ 40 mm | ≥ 27 mm |
| 29 | 23 - 26 mm | 415 - 572 mm2 | 72.3 - 84.8 mm | ≤ 43 mm | ≥ 29 mm |
| 31 | 26 - 29 mm | 531 - 660 mm2 | 81.7 - 91.7 mm | ≤ 43 mm | ≥ 29 mm |
Prosthesis aortic sizes by the industry, Expert system and previous medical decision.
| Patient | Industry | Expert System | Medical | Same |
|---|---|---|---|---|
| CV-01 | 29 | 29 | 26 | No |
| CV-02 | 31 | 31 | 29 | No |
| CV-03 | No prosthesis available | No prosthesis available | 29 | No |
| CV-04 | 26 | 26 | 29 | No |
| CV-05 | 29 | 29 | 29 | Yes |
| CV-06 | 29 | 29 | 26 | No |
| CV-07 | 29 | 29 | 29 | Yes |
| CV-08 | 31 | 31 | 29 | No |
| CV-09 | 31 | 31 | 29 | No |
| CV-10 | 31 | 31 | 31 | Yes |
| CV-11 | 29 | 29 | 29 | Yes |
| CV-12 | 29 | 29 | 31 | No |
| CV-13 | 31 | 31 | 29 | No |
| CV-14 | 29 | 29 | 29 | Yes |
| CV-15 | 29 | 29 | 29 | Yes |
| CV-16 | 29 | 29 | 29 | Yes |
| CV-17 | 31 | 31 | 31 | Yes |
| CV-18 | 29 | 29 | 29 | No |
| CV-19 | 31 | 31 | 29 | No |
| CV-20 | 31 | 31 | 31 | Yes |
| CV-21 | 29 | 29 | 29 | Yes |
| CV-22 | 31 | 31 | 31 | Yes |
Not compatible with any of the available sizes of the CoreValve prosthesis.
Comparison of the patients' baseline characteristics according the group of study.
| Variables | Same indication | Divergent indication | |
|---|---|---|---|
| Female gender | 3 (25%) | 2 (20%) | 1.000 |
| Age (years) | 84.8±3.4 | 79.9±7.2 | 0.073 |
| Body mass index (kg/m2) | 24.3±3.7 | 25.2±2.7 | 0.556 |
| Previous cardiovascular surgery | 4 (33.3%) | 2 (20%) | 0.646 |
| Systemic arterial hypertension | 11 (91.7%) | 9 (90%) | 1.000 |
| Diabetes mellitus | 3 (25%) | 1 (10%) | 0.594 |
| Chronic or acute renal injury | 5 (41.7%) | 5 (50%) | 1.000 |
| Creatinine (mg/dl) | 1.81±1.55 | 1.87±1.17 | 0.922 |
| Myocardial infarction | __ | 1 (10%) | 0.455 |
| Stroke | 2 (16.7%) | 1 (10%) | 1.000 |
| Coronary disease | 7 (58.3%) | 2 (20%) | 0.099 |
| Tabagism | 1 (8.3%) | 1 (10%) | 1.000 |
| Obstructive pulmonary disease | 1 (8.3%) | 3 (30%) | 0.293 |
| Peripheral arteriopathy | __ | 1 (10%) | 0.455 |
| Atrial fibrillation | 4 (33.3%) | 5 (50%) | 0.666 |
| Atrioventricular block | __ | 2 (20%) | 0.195 |
| Ejection fraction of left ventricle (%) | 58.7 ±19.1 | 56.2±16.1 | 0.742 |
| Aortic medium gradient (mmHg) | 45.1 ±15.7 | 46.5±17.4 | 0.844 |
| Aortic maximum gradient (mmHg) | 68.5 ±72.8 | 72.8±23.6 | 0.684 |
| Aortic annulus area (cm2) | 0.83 ±0.21 | 0.69±0.19 | 0.143 |
| EuroSCORE I (%) | 21.1 ±12.2 | 15.5±9.3 | 0.249 |
| EuroSCORE II (%) | 8.0 ± 6.3 | 4.7±2.8 | 0.147 |
| STS Score (%) | 7.5 ± 6.2 | 6.8±6.4 | 0.782 |
| Observant Score (%) | 4.8 ± 4.8 | 4.7±3.0 | 0.957 |
Fig. 2Boxplot graphs showing the difference in the post-operative aortic valve gradients according to prosthesis indication.
Outcome incidences after transcatheter aortic valve procedure.
| Outcomes | Same Indication | Divergent indication | |
|---|---|---|---|
| Myocardial infarction | 1 (8.3%) | __ | 1.000 |
| Stroke | __ | 1 (10%) | 0.455 |
| Atrial fibrillation | 2 (16.7%) | 1 (10%) | 1.000 |
| Atrioventricular block | 2 (16.7%) | 1 (10%) | 1.000 |
| Aortic regurgitation | 5 (41.7%) | 3 (30%) | 0.675 |
| Aortic leak | 4 (33.3%) | 5 (50%) | 0.666 |
| Aortic valve mean gradient (mmHg) | 7.7±4.7 | 12.6±9.1 | 0.121 |
| Aortic valve maximum gradient (mmHg) | 11.9±7.6 | 23.9±15.6 | 0.030 |
| 30-day mortality | 2 (16.7%) | 1 (10%) | 1.000 |
| Abbreviations, acronyms & symbols | |
|---|---|
| TAVI | = Transcatheter aortic valve implantation |
| Authors' roles & responsibilities | |
|---|---|
| AMR | Conception and design of work; acquisition, analysis and interpretation of the data; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| JF | Acquisition and interpretation of data; final approval of the version to be published |
| PN | Acquisition and analysis of data; final approval of the version to be published |
| GC | Acquisition and interpretation of data; final approval of the version to be published |
| SC | Final approval of the version to be published |
| MRPN | Final approval of the version to be published |
| FAL | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |